CRISPR Therapeutics AG
SEC filing briefings for CRISPR Therapeutics AG (Nasdaq: CRSP). We track recent EDGAR submissions and summarize what those excerpts disclose — typically filing status, exchange listing, and corporate identifiers — and note when disclosed material (financials, guidance, pipeline updates) is absent.
Past bets that played out
Recent document excerpts are primarily cover pages and table-of-contents material from CRISPR Therapeutics’ Form 10‑Q and Form 10‑K filings (including FY2025 10‑K and multiple quarterly 10‑Qs). These confirm continued SEC reporting and Nasdaq listing (CRSP) but do not include financial results, MD&A, guidance, cash-runway data, pipeline milestones, or risk-factor changes. As provided, they are minimally actionable for trading decisions.
The provided excerpt is only the cover/table-of-contents portion of CRISPR Therapeutics’ Form 10-Q for quarter ended 2026-03-31. It confirms filing status, exchange listing (Nasdaq: CRSP), and basic corporate identifiers, but contains no financial results, guidance, pipeline updates, cash runway, risk-factor changes, or other value-moving disclosures. As-is, it is not tradable/actionable.
This excerpt is only the cover page/header of CRISPR Therapeutics’ FY2025 Form 10‑K (fiscal year ended 2025‑12‑31). It contains listing/filing status information but no financial results, guidance, risk updates, pipeline progress, or MD&A detail—so it provides minimal tradable signal by itself.
Provided excerpt is only the cover/header portion of CRISPR Therapeutics AG’s Form 10-Q for the quarter ended 2025-06-30 (listing symbol/exchange and SEC filing compliance checkboxes). It contains no financial statements, guidance, program updates, or risk-factor changes, so it is minimally actionable for trading beyond confirming continued reporting/listing compliance.
What this channel is watching now
Our current focus is on monitoring CRSP SEC filings for any substantive disclosures beyond header/cover pages: full financial statements, cash position and burn, guidance, clinical program updates, material contracts, or risk-factor amendments. The provided excerpts confirm compliance but contain no incremental operational or financial detail.
Latest videos and market context
Recent YouTube posts from this source. Create an account to unlock live alerts and the full research trail.
SNBR 10-Q report for 2026-04-04
This excerpt is only the cover page/header of Sleep Number’s Form 10-Q for the quarter ended April 4, 2026. It contains filing metadata (issuer, ticker, exchange, address) but no financial statements, MD&A, guidance, risks, or operational commentary. As a result, it is not directly actionable for trading beyond confirming the filing exists.
SOUN 10-Q report for 2026-03-31
The provided excerpt is only the cover/filing header of SoundHound AI, Inc.’s 10‑Q for the quarter ended 2026‑03‑31. It contains listing/security identifiers (SOUN, SOUNW) but no financial statements, MD&A, guidance, risk updates, liquidity details, or material events. As a result, there is insufficient information to form high-confidence, actionable bullish/bearish theses beyond generic “company filed its 10‑Q” metadata.
WEAT 10-Q report for 2026-03-31
The provided excerpt is only the boilerplate cover/filing-status section of Teucrium Commodity Trust’s Form 10‑Q for period ended 2026‑03‑31, with no portfolio holdings, performance, risk, or material updates included. As-is, it contains no actionable investment information beyond confirming the existence of the filing and the issuer/ticker identity (WEAT).
ACHR 10-Q report for 2026-03-31
The provided text is only the cover/header portion of Archer Aviation’s Form 10‑Q for the quarter ended 2026‑03‑31 (issuer identity, exchange listing, and securities outstanding). It contains no operating/financial results, guidance, liquidity details, backlog, or risk-factor updates—so it is minimally actionable for trading beyond basic security identifiers and a generic dilution/optionality consideration from warrants.
Proof-backed call history
We have evaluated multiple recent CRISPR Therapeutics filing excerpts across FY2025 and Q1–Q2 2026. Across four evaluated excerpts the team recorded an average return of -23.36% (evaluatedCount: 4) with a 100% win rate on the specific recommendation set to treat the excerpts as non-actionable due to lack of material content.
The provided excerpt is only the cover/table-of-contents portion of CRISPR Therapeutics’ Form 10-Q for quarter ended 2026-03-31. It confirms filing status, exchange listing (Nasdaq: CRSP), and basic corporate identifiers, but contains no financial results, guidance, pipeline updates, cash runway, risk-factor changes, or other value-moving disclosures. As-is, it is not tradable/actionable.
This excerpt is only the cover page/header of CRISPR Therapeutics’ FY2025 Form 10‑K (fiscal year ended 2025‑12‑31). It contains listing/filing status information but no financial results, guidance, risk updates, pipeline progress, or MD&A detail—so it provides minimal tradable signal by itself.
This excerpt is only the cover/boilerplate of CRISPR Therapeutics’ 10‑Q for the quarter ended 2025‑09‑30 and does not include financial results, cash runway, pipeline updates, guidance, or risk-factor changes. As provided, it offers minimal tradable, incremental information beyond confirming continued SEC reporting/listing compliance.
Provided excerpt is only the cover/header portion of CRISPR Therapeutics AG’s Form 10-Q for the quarter ended 2025-06-30 (listing symbol/exchange and SEC filing compliance checkboxes). It contains no financial statements, guidance, program updates, or risk-factor changes, so it is minimally actionable for trading beyond confirming continued reporting/listing compliance.
About this channel
This feed summarizes short-form EDGAR observations for CRISPR Therapeutics AG (Nasdaq: CRSP). Entries typically represent document cover/header pages; our notes highlight the limited scope of those excerpts and advise that meaningful trading or valuation decisions require the complete filings (financial statements, MD&A, clinical program disclosures, and risk factors).
SEC EDGAR quarterly and annual company filings
Most recognized assets
Unlock the full track record
For actionable analysis, obtain the full Form 10‑Q/10‑K filings or company press releases that include financial statements, guidance, clinical readouts, or material corporate developments. Contact the research desk to request full-document extraction and a deeper read of MD&A, liquidity disclosures, and program updates.